Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

1 year ago 60

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

1. Homepage
2. Breast Cancer
3. Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer